Screener
TG Therapeutics TGTX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $240.34M+70.3% | $204.92M+69.6% | $192.57M+78.0% | $161.71M+92.8% | $141.15M+92.1% | ||
| $41.19M+118% | $33.51M+116% | $38.14M+148% | $28.09M+201% | $18.94M+128% | ||
| $199.14M+62.9% | $171.41M+62.8% | $154.43M+66.4% | $133.62M+79.3% | $122.21M+87.5% | ||
| 82.9%-3.7pp | 83.6%-3.5pp | 80.2%-5.6pp | 82.6%-6.2pp | 86.6%-2.1pp | ||
| $95.34M+200% | $48.4M+4.4% | $41.19M+72.5% | $40.88M+103% | $31.78M+81.0% | ||
| $82.13M+47.8% | $88.22M+75.3% | $62.75M+61.0% | $63.37M+51.0% | $55.59M+43.3% | ||
| $218.66M+106% | $170.12M+51.6% | $142.08M+81.6% | $132.34M+85.2% | $106.31M+64.4% | ||
| $21.67M-37.8% | $34.8M+304% | $50.49M+68.6% | $29.37M+136% | $34.84M+295% | ||
| 9%-15.7pp | 17%+9.8pp | 26.2%-1.5pp | 18.2%+3.3pp | 24.7%+12.7pp | ||
| $16.57M+147% | $7.67M+13.5% | $6.53M-7.5% | $6.72M-38.0% | $6.72M+68.9% | ||
| -$11.44M-192% | -$14.43M-358% | -$5.4M-20.1% | -$3.46M+57.7% | -$3.92M-73.2% | ||
| $10.23M-66.9% | $20.36M+272% | $45.09M+77.2% | $25.91M+507% | $30.92M+372% | ||
| $2.45M-10.2% | $586K+43.6% | $0-100% | -$364.99M-94,169% | $2.73M+933% | ||
| $7.78M-72.4% | $19.78M+291% | $23.04M-1.3% | $390.9M+9,975% | $28.19M+310% | ||
| 3.2%-16.7pp | 9.7%+5.5pp | 12%-9.6pp | 241.7%+237pp | 20%+10.6pp | ||
| $0.05-70.6% | $0.12+300% | $0.150.0% | $2.43+12,050% | $0.17+325% | ||
| $21.73M-37.7% | $34.83M+304% | $50.52M+68.6% | $29.38M+136% | $34.86M+295% | ||
| 9%-15.7pp | 17%+9.9pp | 26.2%-1.5pp | 18.2%+3.3pp | 24.7%+12.7pp | ||
| $21.67M-37.8% | $34.8M+304% | $50.49M+68.6% | $29.37M+136% | $34.84M+295% |
FAQ
- What is TG Therapeutics's revenue?
- TG Therapeutics (TGTX) generated $799.5M in revenue over the trailing twelve months, up 76.1% year over year.
- Is TG Therapeutics profitable?
- TG Therapeutics reported $441.5M in net income over the trailing twelve months, a 55.2% net margin.
- What are TG Therapeutics's profit margins?
- Gross margin is 82.4% and operating margin is 17.1%, with a 55.2% net margin.
- What is TG Therapeutics's earnings per share?
- TG Therapeutics's diluted EPS over the trailing twelve months is $2.75.
- Where does TG Therapeutics's income statement data come from?
- Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
